Global producer of clinical systematic reviews, contributing evidence synthesis authority and multilingual health communication expertise to EU consortia.
The Cochrane Collaboration is the world's foremost producer of systematic reviews in healthcare — independent, peer-reviewed syntheses of clinical trial evidence used by clinicians, policymakers, and researchers to make informed decisions. In H2020, Cochrane contributed its evidence synthesis authority to two language and communication projects: HimL (Health in my Language), which explored digital multilingual delivery of health information to patients, and INTERACT, an international network focused on translation and communication under crisis conditions. Their core value in any consortium is access to a global network of healthcare researchers, an internationally recognized brand for evidence quality, and rigorous methodology for evaluating and communicating complex information across languages and audiences.
Cochrane's participation in both HimL and INTERACT drew on their established capacity to curate, synthesize, and communicate healthcare evidence across diverse contexts and audiences.
HimL (Health in my Language, 2015-2018) directly targeted the challenge of delivering health content in patients' own languages, an area where Cochrane's multilingual review network is immediately applicable.
INTERACT (2017-2020) — the International Network on Crisis Translation — extended Cochrane's work into accurate, rapid translation of critical information under emergency or crisis conditions.
The two H2020 projects suggest a trajectory from health-specific digital communication (HimL, 2015-2018, Digital sector) toward broader multilingual crisis communication (INTERACT, 2017-2020, Research Excellence sector). No keyword data is available to confirm this reading, so the shift is inferred from project titles and sector classifications alone. Given only two projects, this is a weak directional signal rather than a confirmed strategic trend.
Cochrane appears to be extending from patient-facing health content toward broader translation and crisis communication networks — suggesting potential relevance to emergency response, humanitarian, and public health communication consortia beyond clinical settings.
Cochrane participates exclusively as a consortium member in H2020 — never as a coordinator — indicating they contribute specialist authority and credibility rather than taking on project management responsibilities. With 13 unique partners across only two projects, their network is active and geographically diverse, and no repeated partners appear in this data, pointing to broad but non-exclusive collaboration patterns. This profile is typical of a high-visibility reference organization that is brought in to validate evidence standards and lend institutional credibility to project proposals.
Cochrane's H2020 footprint spans 13 unique partners across 9 countries from just two projects, reflecting strong cross-European reach relative to the size of their project portfolio. No geographic concentration is apparent from this data, consistent with their globally distributed organizational model.
Cochrane is the only H2020 participant whose brand is globally synonymous with clinical evidence quality — no other NGO carries the same weight with healthcare policymakers, regulators, and clinicians worldwide. For any consortium addressing patient information, public health communication, or evidence-based digital health tools, Cochrane's presence signals methodological rigor to evaluators and end users alike. Their combination of a globally distributed volunteer researcher network and a recognized evidence grading methodology makes them a rare asset in projects where scientific credibility and public trust are success factors.
